<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456544</url>
  </required_header>
  <id_info>
    <org_study_id>20180122</org_study_id>
    <nct_id>NCT03456544</nct_id>
  </id_info>
  <brief_title>Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China</brief_title>
  <official_title>Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the current situation of vancomycin&#xD;
      (VAN)-associated acute kidney injury (VA-AKI) in China and identify the risk factors for&#xD;
      VA-AKI, as well as to comprehensively examine the risk related to concurrent drug use.&#xD;
      Further, the investigators assessed the outcomes of patients who developed VA-AKI and the&#xD;
      risk factors for these outcomes. Finally, the investigators aimed to provide suggestions for&#xD;
      improving the prevention and treatment of VA-AKI in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vancomycin-associated acute kidney injury(VAN-AKI) occuration rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAN-AKI detection rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDM detction rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>0h Serum creatinine detction rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>48h Serum creatinine detction rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Vancomycin</condition>
  <condition>Staphylococcal Infections</condition>
  <condition>Adverse Effect</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>Cross-sectional Study</condition>
  <arm_group>
    <arm_group_label>VAN-AKI</arm_group_label>
    <description>Patients who had vancomycin associated acute kidney injury.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>None VAN-AKI</arm_group_label>
    <description>Patients who didn't have vancomycin associated acute kidney injury.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.</description>
    <arm_group_label>VAN-AKI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who use vancomycin from all centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Using Vancomycin&#xD;
&#xD;
          -  â‰¥18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical records were incomplete&#xD;
&#xD;
          -  Had been diagnosed with stage 5 CKD or were regularly receiving dialysis&#xD;
&#xD;
          -  SCr were not being adequately monitored to detect the development of AKI&#xD;
&#xD;
          -  Had undergone nephrectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lingyun Ma</last_name>
    <phone>008601066110802</phone>
    <email>haily618@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lingyun Ma</last_name>
      <phone>008601066110802</phone>
      <email>haily618@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Cui Yimin</investigator_full_name>
    <investigator_title>Chief pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

